BASKING RIDGE, N.J., April 6, 2023 /PRNewswire/ -- Torrent Pharma has begun shipping the generic version of Xeris's Keveyis® (dichlorphenamide), 50mg tablets, following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application. Torrent is distributing the product through select specialty pharmacies beginning this month. nnDichlorphenamide Tablets are indicated for the treatment of primary hyperkalemic periodic paralysis and related variants. nnPrimary periodic paralysis (PPP) is a rare condition that causes sudden episodes that affect the muscles, resulting in extreme muscle weakness or temporary paralysis – most often the inability to move the muscles of the arms and legs.
Torrent's Generic Dichlorphenamide Receives Approval in the U.S.
DUBLIN, Ireland and TREVOSE, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today reported financial results for the third quarter of 2020 and provided a corporate update.
Another lawmaker is taking on a pharmaceutical company for drug pricing. Following a report in the Washington Post, Sen. Claire McCaskill, a Missouri Democrat, sent a letter to the president of Strongbridge Biopharma regarding the escalating price of Keveyis, a drug that has gone from free of charge to more than $15,000.
Taro Pharmaceutical Industries Ltd., a multinational, science-based pharmaceutical company, announced that Keveyis (dichlorphenamide) 50 mg tablets, the first medicine approved by the US Food and Drug Administration (FDA) for the treatment of primary hyperkalemic and hypokalemic periodic paralysis and related variants, is now available for appropriate patients through its specialty pharmacy partner, Diplomat.
The shares of Sun Pharmaceutical Industries headed for the fourth day of gains on Friday as they jumped over 3 per cent in noon trade on hopes that company’s paralysis drug Keveyis may boost sales.